Use of anti-tnf.alpha.antibodies and another drug
CA 2385777 A1 · Owner: Chartash, Elliot · Inventors: Fischkoff, Steven; Chartash, Elliot
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to a method of treating disorders in which TFN.alpha. activity is detrimental via biweekly subcutaneous administration of human , antibodies preferably recombinant human antibodies that specifically bind to human tumor necrosis, factor a (hTNF.alpha.) in combination with another drug which is useful for treating the disorder. An antibody of the invention can be a full-length antibody or an antigenbinding portion, thereof. Kits containing a pharmaceutical composition and instructions for dosing are also, encompassed by the invention.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 10, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 10, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 10, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.